Onsdag 15 April | 01:37:51 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-11-26 08:00 Kvartalsrapport 2026-Q3
2026-08-27 08:00 Kvartalsrapport 2026-Q2
2026-05-28 08:00 Kvartalsrapport 2026-Q1
2026-04-10 - X-dag ordinarie utdelning CURAS 0.00 DKK
2026-03-25 - Årsstämma
2026-02-26 - Bokslutskommuniké 2025
2025-12-29 - Extra Bolagsstämma 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-28 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-04-11 - X-dag ordinarie utdelning CURAS 0.00 DKK
2025-02-27 - Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-07-02 - Extra Bolagsstämma 2024
2024-05-23 - Kvartalsrapport 2024-Q1
2024-03-22 - X-dag ordinarie utdelning CURAS 0.00 DKK
2024-03-21 - Årsstämma
2024-02-22 - Bokslutskommuniké 2023
2023-11-23 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-03-31 - X-dag ordinarie utdelning CURAS 0.00 DKK
2023-03-30 - Årsstämma
2023-02-23 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-24 - Kvartalsrapport 2022-Q1
2022-04-27 - Årsstämma
2022-03-25 - X-dag ordinarie utdelning CURAS 0.00 DKK
2022-02-24 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-01 - Extra Bolagsstämma 2021
2021-05-20 - Kvartalsrapport 2021-Q1
2021-03-26 - X-dag ordinarie utdelning CURAS 0.00 DKK
2021-03-25 - Årsstämma
2021-02-24 - Bokslutskommuniké 2020
2020-11-30 - Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen har sitt huvudsakliga fokus inom utvecklingen av innovativa teknologier för diagnostik och behandling av cancer baserat på målstyrd PET-avbildning och radionuklidterapi. Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-03-25 17:14:00

Copenhagen, Denmark, 25 March 2026 - today Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

Today, the shareholders in Curasight passed the following resolutions at the Annual General Meeting in accordance with the agenda:

  1. The Board of Directors' report on the Company's activities in the past financial year

The general meeting took note of the Board of Directors' report on the Company's activities in 2025.

  1. Presentation and approval of the annual report

The general meeting adopted the Company's annual report for 2025 unanimously with all votes represented at the general meeting.

  1. Resolution on appropriation of profit or covering of loss as recorded in the adopted annual report

The general meeting adopted the proposal to carry forward the result for 2025 to the next year according to the adopted annual report for 2025 with all votes represented at the general meeting.

  1. Election of members to the Board of Directors

The general meeting re-elected Kirsten Aarup Drejer, Andreas Kjær, and Ulrich Krasilnikoff as members of the Board of Directors and elected Marcel Reichen and Colin Hayward as new board members replacing Lars Trolle and Charlotte Vedel with consent of all votes represented at the general meeting.

  1. Election of auditor

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor with consent of all votes represented at the general meeting.

  1. Proposed resolutions from the Board of Directors and/or the shareholders of the Company

There were no proposed resolutions from the Board of Directors and/or the shareholders of the Company.

At a board meeting held immediately after the Annual General Meeting, Kirsten Drejer was re-elected as chairman of the Board of Directors and Andreas Kjær was elected as deputy chairman of the Board of Directors.